Abiopharma

🔍 Swayze Eric (Executive)

Company: IONIS PHARMACEUTICALS INC (IONS)

Report Date: 2026-02-13

Detailed Transactions and Holdings:

• Sold 9,435 shares of Common Stock at $81.5592 per share (Direct)
  Date: 2026-02-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,312.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 6,207 shares of Common Stock at $82.0691 per share (Direct)
  Date: 2026-02-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 32,105.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-02-13 | Code: H | nature_of_ownership: by Son | shares_owned_after: 318.00

Footnotes:

• F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.76 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.315 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.